Highest-materiality recent filing
Ginkgo Bioworks Q1 revenue $19M (-49% YoY); narrows net loss; cash burn guidance reaffirmed
Revenue $19M, down 49% YoY; prior year included $7M non-cash deferred revenue release; adjusted EBITDA -$42M.
Ginkgo completes sale of Biosecurity segment to Tower Biosecurity, retains 20% stake
On April 3, 2026, Ginkgo contributed all Biosecurity equity to Tower Biosecurity (Perimeter Systems) for ~20% of buyer's fully diluted shares.
Ginkgo Bioworks sells Biosecurity segment to Tower Biosecurity for 20% stake
Ginkgo contributes all equity of Ginkgo Biosecurity, LLC (its Biosecurity segment) to Tower Biosecurity.
Q4 2025 total revenue $33M, down 24% YoY; Cell Engineering $26M (-26%), Biosecurity $7M (-22%).
Ginkgo Q3 revenue $39M (-56% YoY); net loss $81M; reaffirms FY guide $167-187M
Total revenue $39M, down 56% YoY; prior year had $45M non-cash deferred revenue; ex that, down 11%.
Ginkgo Q2 2025 revenue $50M, net loss $60M; achieves $250M cost savings goal ahead of schedule
Total revenue $50M, down from $56M YoY; Cell Engineering rev up 8% to $39M; Biosecurity down to $10M.
Ginkgo CFO Dmytruk to resign May 30; CAO Coen appointed CFO
Mark Dmytruk resigns as CFO, effective May 30, 2025, to accept a position at another organization.
Ginkgo Bioworks Q1 revenue up 27% to $48M, guided revenue raised; net loss narrows to $91M
Q1 2025 total revenue $48M (+27% YoY); core revenue ex-deferred release $41M (+8%). GAAP net loss $(91)M vs $(166)M prior year.
Ginkgo Q4 2024 revenue $44M (+26% YoY); net loss improves to $(108)M; 2025 rev guidance $160-180M
Q4 total revenue $44M (up 26% YoY); Cell Engineering rev $35M (+29% YoY), Biosecurity $9M.
Total revenue $89M (+61% YoY) incl. $45M non-cash deferred revenue; core rev $44M (-21%).
NYSE to delist Ginkgo Bioworks warrants for abnormally low price; common stock regains compliance
NYSE notified Ginkgo on Sept 3, 2024 to delist warrants (DNA.WS) due to 'abnormally low' trading prices; trading suspended immediately.
Ginkgo Bioworks files 1-for-40 reverse stock split effective August 19, 2024
Reverse stock split of all common stock classes at a 1:40 ratio, effective August 19, 2024.
Ginkgo Bioworks shareholders approve reverse split; board sets 1:40 ratio
Reverse stock split approved by shareholders (4.7B votes for); board set ratio at 1:40.
Ginkgo Q2 revenue down 30% to $56M, launches RIF cutting 35% of workforce for >$85M annual savings
Q2 total revenue $56M vs $81M YoY; Cell Engineering $36M (-20%), Biosecurity $20M (41% gross margin).
Ginkgo Bioworks expands restructuring: at least 35% workforce reduction, $12M+ severance costs
Workforce reduction expanded from 25% labor expense cut to 35% headcount reduction; implementation began June 17, 2024.
Ginkgo Bioworks receives NYSE delisting notice for stock price below $1 for 30 trading days
NYSE notified Ginkgo on May 7, 2024 that average closing price of Class A common stock was below $1.00 over 30 consecutive trading days.
Q1 total revenue $38M, down 53% YoY; Cell Engineering $28M (-18%), Biosecurity $10M.
Ginkgo Bioworks FY2023 revenue $251M (-47% YoY); guides FY2024 total revenue $215-235M
Cell Engineering services revenue $139M (+31% YoY); added 78 new Cell Programs in 2023.
Ginkgo Bioworks expects to meet 2023 revenue guidance of $250-260M; cash nearly $950M
Preliminary cell engineering revenue $145-150M, biosecurity up to $110M, total revenue $250-260M.
Ginkgo Q3 2023: Total revenue $55M (-17% YoY); Cell Engineering up 51%; revises FY23 outlook
Cell Engineering revenue $37M (+51% YoY); Biosecurity revenue $18M with 62% gross margin.
Zymergen subsidiary files Chapter 11; Ginkgo to acquire IP assets as stalking horse bidder
Zymergen Inc., a wholly-owned subsidiary of Ginkgo, filed voluntary Chapter 11 petitions on October 3, 2023 in Delaware.
Ginkgo Bioworks partners with Google Cloud for AI biology tools; up to $56.3M funding
Five-year partnership to develop large language models for biology on Google Cloud's Vertex AI platform.
Ginkgo Q2 revenue $81M (-44% YoY); Cell Engineering services up 72%; guides FY23 rev $245-260M
Q2 total revenue $81M, down 44% YoY as Biosecurity K-12 testing wound down.
Ginkgo Bioworks Q1 revenue $81M, down 52% YoY; Cell Engineering rev up 59%
Q1 2023 total revenue $81M (down 52% YoY); Cell Engineering rev $34M (+59% YoY); Biosecurity rev $47M (52% gross margin).
Ginkgo Bioworks discloses ~$74M exposure to failed Silicon Valley Bank via Zymergen subsidiary
Zymergen subsidiary holds ~$74M (6% of total cash) at Silicon Valley Bank.
Ginkgo Bioworks reports 2022 revenue up 52% to $478M; guides 2023 total revenue at least $275M
Full year 2022 total revenue $478M (+52% YoY); Foundry $144M (+27%), Biosecurity $334M (+66%).
Ginkgo expects to meet 2022 total revenue guidance of $460-480M; cash ~$1.3B
Expects 55-60 new Cell Programs added in 2022, nearly doubling 2021 additions.
Ginkgo Q3 rev down 14% to $66M; raises FY22 revenue guidance to $460-480M
Total revenue $66M (down 14% YoY); Foundry $25M (down 29%), Biosecurity $42M (down 3%).
Ginkgo Bioworks completes acquisition of Zymergen; exchange ratio 0.9179
Acquisition closed on October 19, 2022, per the merger agreement signed July 24, 2022.
Ginkgo Q2 revenue $145M (+231% YoY); guides total revenue to $425-440M
Foundry revenue $44M (+105% YoY); added 13 new Cell Programs in Q2.
Ginkgo to acquire Bayer's agricultural biologics R&D platform for ~$83M
Ginkgo acquires Bayer's 175,000 sq ft West Sacramento Biologics R&D site and team for ~$83M in cash or stock.
Ginkgo to acquire Zymergen for ~$300M all-stock; Zymergen holders get 0.9179 DNA shares
Deal valued at ~$300M market cap; fixed exchange ratio of 0.9179 Ginkgo shares per Zymergen share.
Ginkgo Q1 revenue $168M (+282% YoY); raises FY22 total revenue guidance to $375-390M
Total revenue $168M (+282% YoY); Foundry revenue $21M (-5% YoY); Biosecurity revenue $147M.
Ginkgo Bioworks FY2021 revenue $314M (+309% YoY); 2022 guidance $325-340M
Full-year 2021 total revenue $314M, up 309% YoY; Foundry revenue $113M (+91%), Biosecurity $201M (exceeded $110M outlook).
Mark Dmytruk, the Company’s Chief Financial Officer and principal financial officer, gave notice on May 19, 2025 of his intention to resign from these roles at the Company on May 30, 2025 to accept a position at another organization
Steven Coen, CPA, the Company’s Chief Accounting Officer, will become Chief Financial Officer, principal financial officer and principal accounting officer, effective upon Mr. Dmytruk’s resignation
On November 7, 2024, Dr. Arie Belldegrun resigned from his position as a director of the Board.
On November 6, 2024, the Class B directors of the board of directors (the “Board”) of the Company appointed Dr. Sri Kosuri to the Board as a Class B director.
Marie E. Fallon informed Ginkgo Bioworks Holdings, Inc. (the “Company”) on May 1, 2023 of her intent to resign from her role as Chief Accounting Officer of the Company, effective May 15, 2023.
In connection with Ms. Fallon’s resignation and subject to the approval of the Company’s Board of Directors, on May 5, 2023, the Company appointed Steven P. Coen, age 57, as its Chief Accounting Officer, effective May 15, 2023.
On August 2, 2022, the Board of Directors (the “Board”) of Ginkgo Bioworks Holdings, Inc. (the “Company”) voted to appoint Kathy Hopinkah Hannan to the Board, effective as of August 2, 2022.
Ms. Shetty was appointed as President and Chief Operating Officer;
Jason Kelly, Reshma Shetty, Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar and Harry E. Sloan were appointed as directors of the Company.
Scott M. Delman, Joshua Kazam, Isaac Lee, Timothy Leiweke, Dennis A. Miller, Laurence E. Paul, and Harry E. Sloan ceased serving on SRNG’s board of directors.
Jason Kelly, Reshma Shetty, Arie Belldegrun, Marijn Dekkers, Christian Henry, Reshma Kewalramani, Shyam Sankar and Harry E. Sloan were appointed as directors of the Company.
Mark Dmytruk was appointed as Chief Financial Officer.
Max materiality 0.90 · Median 0.68 · Most common event earnings